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Context:  Treatment  of infected  nasal  polyposis.
Material  and  methods:  Multicenter  interventional  prospective  double-blind  randomized  study  with
matched  groups:  treatment  with  tobramycin  aerosol  versus  isotonic  saline  aerosol.  The  study  popu-
lation  included  55  patients:  23  receiving  isotonic  saline  aerosol  and  32 receiving  tobramycin.  A novel
device  (Easynose®) was  used  with  an  original  principle  limiting  pulmonary  deposition  and  ensuring
homogeneous  peripheral  deposition  in the  nasal cavities.
Objectives:  The  principal  objective  was  to  compare  bacteriological  eradication  between  tobramycin
150  mg/3  ml  versus  isotonic  saline,  both  administered  by  nebulization  via the  Easynose®
device.
Results  and conclusion:  Tobramycin  aerosol  administered  via  the  Easynose® device  showed  signiﬁcantly
better  bacteriological  eradication  than  isotonic  saline.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Nasal polyposis (NP) is a chronic inﬂammatory disease of the
inonasal mucosa, with prevalence of about 4% [1]. It is character-
zed by essentially bilateral ethmoid and nasal cavity polyps [2].
The few bacteriological studies of NP are concordant, showing
0–80% of cultures pathogen-positive [3–5]. Isolates mainly com-
rise Staphylococcus aureus (40–60% of samples), Pseudomonas
eruginosa (approx. 5%), Haemophilus spp. (approx. 5%), and Strep-
ococcus pneumoniae (approx. 5%) [4,5]. These rates are the same in
perated and non-operated patients. The isolates are susceptible to
obramycin [3–5]. However, NP course features infectious episodes
ssociating heightened sinus secretion and abundant purulent
ecretion in the nasal cavity [2,3]. These episodes are presently
reated by wide-spectrum systemic antibiotics, sometimes
∗ Corresponding author.
E-mail address: pierre.bonﬁls@egp.aphp.fr (P. Bonﬁls).
http://dx.doi.org/10.1016/j.anorl.2015.03.008
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.associated to oral corticosteroids. No published studies have
demonstrated the efﬁcacy of such treatment, and there are no
published guidelines.
Notably, there are no published data regarding the efﬁ-
cacy of any kind of nebulization aerosol therapy in rhinosinus
pathologies, whether acute or chronic, despite the fact that this
mode of administration seems especially well suited by virtue
of the easy access to the nasal and sinus cavities [6]. It seems
particularly suited to patients undergoing bilateral ethmoidec-
tomy for NP, in view of the wide opening of the sinuses. A
new device was  recently developed by the Diffusion Technique
Franc¸ aise company (Easynose®), based on an original principle
(patent No. FR2938770) that reduces pulmonary deposition and
ensures homogeneous peripheral deposition in the nasal cavities
[7].In the light of these data and this recent innovation, we per-
formed a prospective multicenter study in France to assess the
contribution and limitations of nebulization of tobramycin solution
in infection following surgery for NP.
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Table 1
Comparison of patient data per group. Differences were not signiﬁcant.
Group A
Saline
Group B
Tobramycin
P
n 23 32
Mean age (range) in years 53 (29–70) 46 (22–70) NS
Gender (% male) 43.48 53.13 NS
Time from NP diagnosis (years) 10 13 NS
Time from ethmoidectomy (years) 5 6 NS
%  NP + asthma 17.39 28.1320 P. Bonﬁls et al. / European Annals of Otorhinolary
. Material and methods
.1. Methods
.1.1. Study design
A prospective interventional study randomized patients into
wo matched groups (tobramycin versus isotonic saline neb-
lization) in a double-blind comparative multicenter design.
andomization was balanced (ratio 1:1), based on a list comprising
ize-4 blocks. Patients randomly received either tobramycin (group
) or isotonic saline (group A). The local review board (Comité
e Protection des Personnes [CPP] Île-de-France VIII) approved the
esearch protocol on October 8, 2010.
.1.2. Treatment
The active treatment was a solution of 150 mg  tobramycin
or inhalation by nebulization in a single dose of 3 ml  medium
150 mg/3 ml), administered by the Easynose®mesh nebulizer. The
olution was composed of tobramycin 150 mg,  water for injec-
ion qs 3 ml,  and NaCI. The isotonic saline solution comprised the
xcipient of the active treatment. Active treatment or saline was
dministered twice daily for 7 days. Long-course corticosteroid
herapy was allowed on condition that there had been no change in
osage for at least 1 month before inclusion. For the duration of the
tudy, patients were not to have any nose-wash with physiological
aline, antibiotherapy or systemic corticotherapy.
.1.3. Study objectives
The principal study objective was to compare bacteriologi-
al eradication efﬁcacy between tobramycin 150 mg/3 ml  solution
ersus isotonic saline, both prepared for inhalation by aerosol neb-
lization using the Easynose® device.
Secondary objectives were:
to compare efﬁcacy between tobramycin 150 mg/3 ml  solution
versus isotonic saline, both prepared for inhalation by aerosol
nebulization using the Easynose® device, in terms of clinical
improvement, adverse effects and study withdrawal
to analyze the acceptability of aerosol nebulization for the
patient.
.1.4. Study variables
To explore the principal objective, bacteriological analysis was
erformed on D0 and D10, following Day et al. [5], studying
he presence of pathogenic strains in culture and their antibiotic
usceptibility, with cytological analysis of the presence and con-
entration of leukocytes (D0 and D10).
Variables exploring the secondary objectives were:
clinical: nasal congestion, anterior and posterior rhinorrhea,
facial pain and heaviness, and olfactory impairment, assessed at
D0, D10 and D30 on visual analog scales (VAS);
acceptability: satisfaction in terms of ease of use of the device
(preparation, inhalation) and duration of application.
Compliance was assessed in terms of failures to take treatment,
eported on a self-assessment questionnaire ﬁlled out at the treat-
ent sessions from D1 to D7, also reporting adverse effects. General
linical examination and ﬁberoptic endoscopy were performed at
0, D7 and D30..1.5. Statistical analysis
Statistical analysis was blind, the two groups being labeled A
nd B (in fact, saline and tobramycin, respectively), identiﬁed only
fter the analysis results were in.%  Widal 39.13 37.50 NS
NS: non-signiﬁcant.
Comparison used:
• Fisher exact test for qualitative data (gender, bacteriology);
• Student t-test or non-parametric Wilcoxon test for continu-
ous quantitative data (age, time from NP diagnosis, time from
last infection episode, time from ethmoidectomy, pre-treatment
VAS);
• Wilcoxon test for ordinal qualitative data (bacteriological quan-
tiﬁcation of strains; cytological quantiﬁcation of leukocytes).
2.2. Material
Inclusion criteria were patient:
• aged 20–70 years, with health insurance cover, consenting to the
study;
• presenting with NP operated on for an episode of infection (aggra-
vation of symptoms, with bilateral purulent secretion) within the
previous 3 months;
• with fully healed total ethmoidectomy performed at least 2
months previously;
• without local or systemic antibiotherapy during the previous
month;
• with NP not extending beyond the roof of the maxillary sinus.
Exclusion criteria were: pregnancy, breast-feeding, cystic ﬁbro-
sis, proven ciliary dyskinesia or known immune deﬁciency, kidney
failure and contraindications for aminoglycosides.
In all, 72 patients were randomized: 33 to group A (saline) and
39 to group B (tobramycin). Ten patients (6 in group A, 4 in group
B) were excluded for negative D0 bacteriology, and 7 (4 in group A
and 3 in group B) for major protocol deviation (age > 70 years, use of
forbidden medication). Thus the ﬁnal study population comprised
55 patients: 23 patients in group A, 32 in group B.
Table 1 presents patient data per group; characteristics were
comparable (P > 0.05). Table 2 presents sinonasal status: symptoms,
septum status, inferior turbinate status, polyposis volume, severity
of purulence; characteristics were comparable.
Table 3 presents percentage positive culture per group; there
was no signiﬁcant difference. Table 4 presents cytologic results
analyzing secretions; there was  no signiﬁcant difference. Table 5
presents the tobramycin susceptibility of isolates: 62 of the
70 strains were tobramycin-susceptible (88.57%), being mainly
streptococci, which are naturally non-susceptible to aminoglyco-
sides. Among the pathogenic strains, only one S. aureus strain had
acquired tobramycin resistance.
3. Results3.1. Compliance
Mean compliance was excellent in both groups: 98.9% in group
A and 97% in group B. There were only 5 failures to take tobramycin.
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Table  2
Comparison of pre-treatment (D0) clinical data per group. Differences were not
signiﬁcant.
D0 Group A
Saline
Group B
Tobramycin
P
n 23 32
Nasal congestiona 45.22 41.72 NS
Anterior rhinorrheaa 37.17 33.50 NS
Posterior rhinorrheaa 62.87 50.69 NS
Sneezinga 21.78 19.69 NS
Facial paina 28.39 25.00 NS
Olfactory impairmenta 79.57 71.19 NS
%  septal deviation 8.70 6.25 NS
%  inferior turbinate hypertrophy 3.70 15.63 NS
%  polypoid obstruction of the ethmoidb 32.65 33.72 NS
Quantiﬁcation of purulent secretionc 49.26 53.19 NS
NS: non-signiﬁcant.
a VAS: 0 (no discomfort) to 100 (intolerable discomfort).
b VAS: 0 (absent) to 100 (complete obstruction up to maxillary sinus roof).
c VAS: 0 (absent) to 100 (severe).
Table 3
Comparison of pre-treatment (D0) bacteriological data per group. Differences were
not signiﬁcant.
n (%) positive culture at D0 Group A
Saline
Group B
Tobramycin
P
n total 23 32
Staphylococcus aureus 14 (60.87%) 19 (59.37%) NS
Streptococcus pneumoniae 2 (8.70%) 5 (15.64%) NS
Streptococcus group A 2 (8.70%) 2 (6.25%) NS
Streptococcus group C 2 (8.70%) 0 NS
Branhamella catarrhalis 1 (4.35%) 1 (3.13%) NS
Haemophilus inﬂuenzae 5 (21.74%) 6 (18.75%) NS
Enterobacteria 4 (17.4%) 3 (9.37%) NS
Pseudomonas aeruginosa 5 (21.74%) 1 (3.13%) NS
Other  strictly aerobic G-bacteria 0 4 (12.5%) NS
N
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Table 6
Comparison of post-treatment (D10) bacteriological data per group (% positive cul-
ture). Differences were signiﬁcant (P = 0.02).
% positive samples at D10 Saline Tobramycin
Staphylococcus aureus 52.17 18.75
Streptococcus pneumoniae 13.04 7.81
Streptococcus group A 6.52 0
Streptococcus group C 4.35 0
Branhamella catarrhalis 4.35 0
Haemophilus inﬂuenzae 13.04 6.25
Enterobacteria 6.52 3.13
Pseudomonas aeruginosa 17.39 1.56S: non-signiﬁcant.
.2. Bacteriological efﬁcacy (D10)
Table 6 presents strain eradication. 46.88% of strains present at
0 had been eradicated by D10 in group B (tobramycin), versus
7.39% in group A (saline) (P = 0.02) (Fig. 1).able 4
omparison of pre-treatment (D0) cytological data per group (% leukocyte presence
n secretions). Differences were not signiﬁcant.
% presence at D0 Group ASaline Group BTobramycin P
No leukocytes 23.81 36.67
Few leukocytes 28.57 30.00
Some leukocytes 23.81 6.67
Many leukocytes 14.29 20.00
Very many leukocytes 9.52 6.67 0.40
able 5
obramycin susceptibility of D0 isolates.
% positive samples at D0 Resistant Susceptible Intermediate Total
Staphylococcus aureus 1 32 0 33
Streptococcus pneumoniae 2 0 5 7
Streptococcus group A 0 0 4 4
Streptococcus group C 1 0 1 2
Haemophilus inﬂuenzae 0 11 0 11
Enterobacteria 0 7 0 7
Pseudomonas aeruginosa 0 6 0 6
Total 4 62 4 70Fig. 1. Percentage bacterial eradication at D10; the difference between the two
groups was signiﬁcant (P = 0.02).
3.3. Clinical efﬁcacy (D10 and D30)
There were no signiﬁcant differences in symptoms between D0
versus D10 or D30: congestion, anterior or posterior rhinorrhea,
sneezing, facial pain or olfactory impairment.
3.4. Early withdrawal
One patient in group A and 4 in group B withdrew from the
study; this difference was not signiﬁcant (P = 0.38). Reasons for
withdrawal were: lack of clinical improvement (n = 1), loss to
follow-up (n = 1), and need for forbidden treatment (notably for
asthma) (n = 3).
3.5. Adverse events
There were in all 27 adverse events, none of which were serious.
The rate of adverse events did not differ between groups (P = 0.58).
Adverse events mainly comprised lower respiratory issues (asthma
attack, cough, bronchitis), otologic issues (otalgia, otitis), gastro-
intestinal issues (diarrhea, nausea) and erythematous skin lesions.
3.6. Aerosol device use
Preparing the substance to be put in the aerosol device was
found easy or very easy by 85.18% of patients in group A and 100%
of patients in group B (non-signiﬁcant). Using the device for inhala-
tion was  found easy or very easy by 100% of patients in both groups.
Mean duration per application was  9 minutes 50 seconds in group
A and 10 minutes in group B (non-signiﬁcant).4. Discussion
Inﬂammatory and infectious episodes associated with nasal
polyposis are problematic due to their recurrence [2]. The
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resent attitude, in the absence of evidence, is based on oral
ntibiotherapy, or oral corticosteroids in severe cases impairing
uality of life. There are no ofﬁcial guidelines.
The adverse side-effects of iterative oral corticosteroids have
een assessed and notably include risk of osteoporosis and kidney
ailure [8]; prescription is limited to not more than 2 short courses
n a given year. The adverse side-effects of iterative systemic antibi-
tics consist in increased bacterial resistance, which is becoming a
ajor medical problem. In NP, prescription of these two  classes of
ystemic medication should therefore be limited. In the early 2000s,
orticosteroids prepared for nasal pulverization came onto the mar-
et, representing a signiﬁcant advance as they show few systemic
ffects [9]. The problem of treating infection episodes, however,
emained. The development of a novel device, Easynose®, with
imited lung deposition and guaranteed homogeneous peripheral
eposition in the nasal and sinus cavities [7], offers the possibility
f aerosol therapy for drug-resistant ethmoid cavity infection fol-
owing ethmoidectomy for NP. This was the focus of the present
tudy.
Tobramycin was selected in the light of a previous study that
ighlighted the very particular bacteriology of the sinonasal cav-
ties in patients operated on for NP [5]: 144 out of 120 samples
95%) were positive on culture. However, 12 of the 60 patients
20%) were colonized exclusively by non-pathogenic bacteria
coagulase-negative staphylococcus, Corynebacterium spp., etc.);
hus only 102 samples (80% of patients) were colonized by
athogens. The present study found comparable positive culture
ates and strain distributions (Table 3). The pathogens isolated
ere:
Gram-positive bacteria: predominantly S. aureus,  plus
S. pneumoniae and group-G streptococci;
Gram-negative bacteria: B. catarrhalis,  H. inﬂuenzae and enter-
obacteria;
strictly aerobic Gram-negative bacteria (e.g., P. aeruginosa), and
other aerobic Gram-negative bacteria.
In the previous study, almost 94% of isolates were tobramycin-
usceptible, and the present study found a very similar rate.
obramycin delivered by aerosol has been fully studied in
hildren with cystic ﬁbrosis, showing good clinical and bacteri-
logical results, leading to market authorization [10,11]. These
ndings led to administration of tobramycin by the Easynose®
nhaler.
The study inclusion criteria (fully healed total ethmoidectomy
t least 2 months previously) ruled out patients in the immediate
ostoperative period and those in whom NP volume could hinder
thmoid cavity deposition. Extension restriction to the roof of the
axillary sinus was logical, to ensure diffusion of the antibiotic
nd easy detection on ﬁberoptic nasal endoscopy in consultation.
xcluding local and general antibiotherapy within 1 month of inclu-
ion was intended to rule out any doubt as to the effect of the study
erosol therapy. To ensure a homogeneous population, patients
ith cystic ﬁbrosis, proven ciliary dyskinesia or known immune
eﬁciency were excluded. Finally, 10 patients were excluded sec-
ndarily (6 in group A and 4 in group B) for lack of D0 bacteriological
ndings (sterile culture), preventing assessment of the effect of the
ntibiotic; this was a low rate of sterile culture (13.8%) for a bacte-
iological study of rhinosinus pathology, where sterile culture rates
re often close to 20%.
The principal study objective was to assess the efﬁcacy of
acteriological eradication by tobramycin 150 mg/3 ml  in nebuliza-
ion aerosol therapy versus isotonic saline, both delivered by the
asynose® device. The principal result was that tobramycin was
igniﬁcantly more effective than saline (P = 0.02) (Fig. 1). This wasgy, Head and Neck diseases 132 (2015) 119–123
probably due to the very high mucosal concentration achieved by
a nebulizer adapted to the sinonasal region.
The secondary objectives were:
• to demonstrate the superiority of tobramycin 150 mg/3 ml  solu-
tion versus isotonic saline, both prepared for inhalation by aerosol
nebulization using the Easynose® device, in terms of clinical
improvement, adverse effects and study withdrawal;
• to demonstrate the acceptability of aerosol nebulization for the
patient.
The ﬁrst of these could not be achieved: despite better eradica-
tion with tobramycin, clinical scores at D10 and D30 did not show
improvement. This was probably due to short follow-up (30 days),
as increased sinonasal inﬂammation following infection in NP is
slow to resolve. The second sub-objective was achieved: patients
rated acceptability as excellent. No adverse events were severe,
and were basically due to the natural evolution of disease (NP
and asthma), not implicating treatment. Mean application time per
inhalation session was  about 10 minutes.
This was thus the ﬁrst study to demonstrate the efﬁcacy of
aerosol antibiotherapy compared to saline administered by the
same device. It was also the ﬁrst to demonstrate the efﬁcacy of neb-
ulization aerosol therapy as a means of drug delivery in a speciﬁc
pathology (NP), with a speciﬁc drug (tobramycin), using a spe-
ciﬁc inhaler (Easynose®). The lack of clinical improvement may
be explained by the short follow-up (30 days) in an inﬂamma-
tory disease in which symptoms are slow to resolve, sometimes
requiring associated general corticotherapy. Adverse events were
not severe, were the same in both groups, and were basically due to
the natural evolution of disease during infection. Administration by
aerosol was well accepted, both as easy to use and short (sessions
not exceeding 10 minutes).
5. Conclusion
This was  the ﬁrst randomized comparative study assessing bac-
terial eradication by nasal nebulization of tobramycin in patients
operated on for nasal polyposis. Tobramycin delivered by the
Easynose® device showed signiﬁcant beneﬁt compared to saline.
Local antibiotherapy for infection in patients operated on for severe
NP can reduce prescription of systemic antibiotics, contributing to
the ﬁght against emergent antibiotic resistance.
Disclosure of interest
The present phase III study received funding from the French
pharmaceutical company Erempharma. Data monitoring and anal-
ysis were performed by the Clinact company.
References
[1] Casale M,  Pappacena M,  Potena M, et al. Nasal polyposis: from pathogenesis to
treatment, an update. Inﬂamm Allergy Drug Targets 2011;10:158–63.
[2] Bonﬁls P. Polypose naso-sinusienne. EMC; 2011. p. 23 [20-395-A-10].
[3] Ramakrishnan VR, Feazel LM,  Abrass LJ, et al. Prevalence and abundance of
Staphylococcus aureus in the middle meatus of patients with chronic sinusitis,
nasal polyps, and asthma. Int Forum Allergy Rhinol 2013;3:267–71.
[4] Cleland EJ, Bassiouni A, Wormald PJ. The bacteriology of chronic rhinosinusitis
and the pre-eminence of Staphylococcus aureus in revision patients. Int Forum
Allergy Rhinol 2013;3:642–6.
[5] Day N, Mainardi JL, Malinvaud D, et al. Bacteriological study of ethmoid
specimens from patients with nasal polyposis after ethmoidal surgery. Ann
Otolaryngol Chir Cervicofac 2009;126:196–202.[6] Dautzenberg B, Bonﬁls P, Diot P, et al. Best clinical practices for aerosol neb-
ulization approved by the National Meeting on Nebulization, Paris, 4–5 April
1997. Ann Otolaryngol Chir Cervicofac 2000;117:327–32.
[7] Vecellio L, De Gersem R, Le Guellec S, et al. Deposition of aerosols delivered by
nasal route with jet and mesh nebulizers. Int J Pharm 2011;407:87–94.
ngolo
[P. Bonﬁls et al. / European Annals of Otorhinolary
[8] Bonﬁls P, Halimi P, Malinvaud D. Adrenal suppression and osteo-
porosis after treatment of nasal polyposis. Acta Otolaryngol 2006;126:
1195–200.
[9] Snidvongs K, Kalish L, Sacks R, et al. Sinus surgery and delivery method
inﬂuence the effectiveness of topical corticosteroids for chronic rhinosi-
nusitis: systematic review and meta-analysis. Am J Rhinol Allergy 2013;27:
221–33.
[gy, Head and Neck diseases 132 (2015) 119–123 123
10] Scheinberg P, Shore E. A pilot study of the safety and efﬁcacy of
tobramycin solution for inhalation in patients with severe bronchiectasis. Chest
2005;127:1420–6.
11] Mainz JG, Schädlich K, Schien C, et al. Sinonasal inhalation of tobramycin
vibrating aerosol in cystic ﬁbrosis patients with upper airway Pseudomonas
aeruginosa colonization: results of a randomized, double-blind, placebo-
controlled pilot study. Drug Des Devel Ther 2014;8:209–17.
